Search Results for: covid-19
Articles
November 19, 2024
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia November 19, 2024
GeoVax Labs, Inc. recently announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for...
September 4, 2024
Invivyd Doses First Participants in Phase 1 Clinical Trial of Next Generation Monoclonal Antibody Candidate for COVID-19 September 4, 2024
Invivyd, Inc. recently announced dosing of the first participants in the Phase 1 healthy volunteer clinical trial of VYD2311, a...
May 29, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development May 29, 2024
ProBioGen recently announced a pivotal collaboration with ModeX Therapeutics an OPKO Health Company dedicated to combating cancer and infectious diseases with cutting-edge….
January 15, 2024
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants January 15, 2024
ExeVir Bio recently announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants....
October 26, 2023
Pfizer & BioNTech Announce Positive Topline Data for mRNA-Based Combination Vaccine Program Against Influenza & COVID-19 October 26, 2023
Pfizer Inc. and BioNTech SE recently announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability, and immunogenicity...
August 10, 2023
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia August 10, 2023
GeoVax Labs, Inc. recently announced vaccinations have begun in an investigator-initiated clinical trial (ClinicalTrials.gov Identifier: NCT05672355) of GEO-CM04S1 in patients...
May 1, 2023
VACCINE TECHNOLOGY - Solving the Challenges & Introducing New Strategies for Influenza & COVID-19 Protection May 1, 2023
Paul Radspinner, MBA, and Pamuk Bilsel, PhD, say with a combination vaccination strategy, the biopharma industry could truly solve the efficacy, durability, and drift problems of current influenza and COVID-19 vaccines.
March 7, 2023
Dyadic Provides Phase 1 Clinical Trial Update for its COVID-19 Recombinant Protein RBD Booster Vaccine Candidate March 7, 2023
Dyadic International, Inc. recently provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor...
October 26, 2022
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 October 26, 2022
eFFECTOR Therapeutics, Inc. recently announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical...
September 1, 2022
Vaxart Announces Positive Top-line Phase 2 Clinical Study Data Demonstrating Safety & Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate September 1, 2022
Vaxart, Inc. recently reported positive top-line data from the first part of a planned two-part Phase 2 study of its...
June 7, 2022
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19 June 7, 2022
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet...
May 12, 2022
Akston Biosciences Doses First Participants in Phase 2 Clinical Trial for Shelf-Stable COVID-19 Booster May 12, 2022
Akston Biosciences Corporation recently announced it dosed the first set of volunteers in an open-label study of AKS-452, its protein...
May 2, 2022
FDA Has Granted Veru a Pre-Emergency Use Authorization Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study May 2, 2022
Veru Inc. recently announced the FDA has granted the company a pre-Emergency Use Authorization (EUA) meeting on May 10, 2022,...
April 21, 2022
Cocrystal Pharma Collaborates With the NIAD to Evaluate COVID-19 Protease Inhibitors April 21, 2022
Cocrystal Pharma, Inc. recently announced a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to….
April 18, 2022
Revive Therapeutics Announces Publication of Research Data With Bucillamine in COVID-19 April 18, 2022
Revive Therapeutics Ltd. recently announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody...
March 17, 2022
Soligenix COVID-19 Vaccine Boosts Neutralizing Activity Against SARS-CoV-2, Including Delta & Omicron March 17, 2022
Soligenix, Inc.recently announced the results of a booster vaccination study using CiVax (heat stable COVID-19 subunit vaccine program) in non-human...
February 28, 2022
Vallon Pharmaceuticals Announces Issuance of US Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated With COVID-19 February 28, 2022
Vallon Pharmaceuticals, Inc. recently announced the United States Patent and Trademark Office (USPTO) has issued patent No. 11,253,490 covering the...
February 24, 2022
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal & Systemic Immune Responses in Non-Human Primates February 24, 2022
A new study published on BioRxiv.org demonstrates that Vaxart’s S-only COVID-19 clinical vaccine candidate, now being studied by Vaxart in...
February 14, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 February 14, 2022
Revive Therapeutics Ltd. recently provided an update on the company’s US FDA Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of….
February 7, 2022
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19 February 7, 2022
Adamis Pharmaceuticals Corporation recently announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of….
